CN1231217C - Medicine for treating climacteric syndrome - Google Patents
Medicine for treating climacteric syndrome Download PDFInfo
- Publication number
- CN1231217C CN1231217C CN 02158544 CN02158544A CN1231217C CN 1231217 C CN1231217 C CN 1231217C CN 02158544 CN02158544 CN 02158544 CN 02158544 A CN02158544 A CN 02158544A CN 1231217 C CN1231217 C CN 1231217C
- Authority
- CN
- China
- Prior art keywords
- group
- medicine
- present
- days
- rat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 72
- 208000011580 syndromic disease Diseases 0.000 title abstract description 17
- 229940079593 drug Drugs 0.000 title description 14
- GFJWACFSUSFUOG-ZJTJBYBXSA-M sodium dehydroepiandrosterone sulfate Chemical compound [Na+].C1[C@@H](OS([O-])(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 GFJWACFSUSFUOG-ZJTJBYBXSA-M 0.000 claims abstract description 29
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- 210000001215 vagina Anatomy 0.000 claims description 34
- 230000000694 effects Effects 0.000 abstract description 20
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 abstract description 18
- 210000004696 endometrium Anatomy 0.000 abstract description 18
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 abstract description 18
- 208000004746 Atrophic Vaginitis Diseases 0.000 abstract description 17
- 230000000711 cancerogenic effect Effects 0.000 abstract description 8
- 231100000315 carcinogenic Toxicity 0.000 abstract description 8
- 230000000638 stimulation Effects 0.000 abstract description 6
- 206010046910 Vaginal haemorrhage Diseases 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 2
- 238000001794 hormone therapy Methods 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 206010046788 Uterine haemorrhage Diseases 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 210000004291 uterus Anatomy 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 30
- 210000002510 keratinocyte Anatomy 0.000 description 30
- 241001465754 Metazoa Species 0.000 description 29
- 210000004907 gland Anatomy 0.000 description 29
- 239000000825 pharmaceutical preparation Substances 0.000 description 28
- 210000001672 ovary Anatomy 0.000 description 20
- 239000000203 mixture Substances 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 16
- 238000009472 formulation Methods 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- 210000000265 leukocyte Anatomy 0.000 description 14
- 238000012360 testing method Methods 0.000 description 11
- WZDGZWOAQTVYBX-XOINTXKNSA-N tibolone Chemical compound C([C@@H]12)C[C@]3(C)[C@@](C#C)(O)CC[C@H]3[C@@H]1[C@H](C)CC1=C2CCC(=O)C1 WZDGZWOAQTVYBX-XOINTXKNSA-N 0.000 description 10
- 238000004140 cleaning Methods 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 238000001000 micrograph Methods 0.000 description 7
- 230000000007 visual effect Effects 0.000 description 7
- 230000003321 amplification Effects 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 229940011871 estrogen Drugs 0.000 description 6
- 239000000262 estrogen Substances 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000011121 vaginal smear Methods 0.000 description 5
- 206010003694 Atrophy Diseases 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 206010027304 Menopausal symptoms Diseases 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000037444 atrophy Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000001076 estrogenic effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 229960002847 prasterone Drugs 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000012173 estrus Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002657 hormone replacement therapy Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000003780 keratinization Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000008183 oral pharmaceutical preparation Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- -1 sulfuric acid ester Chemical class 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 230000001550 time effect Effects 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical group [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000974485 Aricia shasta Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010014756 Endometrial hypertrophy Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010021718 Induced labour Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000008350 Pruritus Vulvae Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000001158 estrous effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000026234 pro-estrus Effects 0.000 description 1
- 230000001072 progestational effect Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to medicine for treating climacteric syndromes, particularly to women senile and atrophic vaginitis and a preparation method thereof. The medicine provided by the present invention contains prasterone sulfate sodium. The medicine overcomes the defects of the existing medicine, has very good therapeutic effect on climacteric syndromes, particularly women senile atrophic vaginitis, has the advantages of small toxic and side effect, and no stimulation to the endometrium, can not cause vaginal bleeding and has no carcinogenic risk brought by an ordinary hormone therapy.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of climacteric syndrome, treat especially that the women is senile, the medicine of atrophic vaginitis.
Background technology
The women will enter into the climacteric period early or late before and after 40 years old.The women in this period will stand light or heavy a series of climacteric syndromes, bring misery to them.At present, normal employing Hormone Replacement Therapy (HRT) is treated menopausal syndrome both at home and abroad.Hormone Replacement Therapy medicine commonly used has doubly beauty, livial (Livial) etc. both at home and abroad.Times beauty has some potential side effect, is stopped using by many countries.Livial (Livial) has the effect of estrogen, androgen and progesterone, and is as imitative steroidal synthetic material, bigger to endometrial stimulation.
Usually, the women has approximately and suffers from atrophic vaginitis more than 30% after menopause.This disease also can occur in behind the excision ovary or the patient behind the malignant tumor pelvic cavity radiotherapy.The pudendum of atrophic vaginitis is the senile atrophy outward appearance more.The patient often is a leucorrhoea grow in quantity, symptom such as pruritus vulvae, pain and dysphoria.The main cause of the endocrinology aspect of these diseases is estrogen deficiencies.At present, adopt vagina cleaning therapy, antibacterials and estrogen to treat both at home and abroad usually.
Though the hormone therapy method is all effective in cure to climacteric syndrome and atrophic vaginitis, do not advocate often to use estrogen clinically and treat atrophic vaginitis, because excessive use estrogen regular meeting causes metrorrhagia, thereby increase carcinogenic danger.That is to say, hormonotherapy has increases carcinoma of endometrium, breast cancer risk (" 8. climacteric of research and postmenopause about menopause use estrogen and progestational hormone medicine to treat the various harm of generation, particularly carcinogenic harm " People's Health Publisher 1985; 55-84) wait side effect, safer, therapeutic effect better medicament that people need seek.
Ideal gonadal hormone alternative medicine is relief of symptoms effectively, prevention urogenital organ atrophy, and bone quickens to lose after the prevention menopause, and the protection cardiovascular function promotes mental health, improves social competence; Can not cause vaginal hemorrhage again; Can not increase carcinogenic danger.
Prasterone is that human acth cortex lamina reticularis produces excretory a kind of hormone precursor.Can participate in the multiple steroid hormone at positions such as synthetic adrenal cortex, testis, ovary.In vivo, itself can be synthetic by cholesterol.Main and the sulfate radical of free prasterone is combined into the form of sulfuric acid ester, and promptly sodium prasterone sulfate enters blood circulation.Prasterone and sodium prasterone sulfate can show androgen and estrogenic two-way activity according to the needs of environment in the human hormone in vivo as a kind of hormone precursor.The sodium prasterone sulfate level keeps normal physical ability and function for keeping the human endocrine environment, and Human Physiology and psychology life-span are all being brought into play important role.The decline of sodium prasterone sulfate content can cause a series of and generation (foreign medical science information 1999 age-related disease in the body; 20 (1): 32).
The main pharmaceutical use of sodium prasterone sulfate is to be used for late trimester of pregnancy, in the stages of labor, the induced labor in late period, impels uterus softening, and it is painful to alleviate childbirth.Facilitate ripe medicine as the pregnant woman uterus mouth is hypogenetic.Up to the present, as treatment climacteric syndrome, the medicine of especially senile, atrophic vaginitis.
Summary of the invention
Technical problem to be solved by this invention provides a kind of treatment climacteric syndrome, the medicine of especially senile, atrophic female vagina, this medicine does not have the caused carcinogenic risk of hormone, the used steroidal substances stimulations bigger to endometrium such as no livial or conventional controversies in hormone replacement in the elderly.
For solving the problems of the technologies described above, the invention provides a kind of treatment climacteric syndrome, the medicine of especially senile, atrophic female vagina, it contains the sodium prasterone sulfate of medicinal effective dose.
A kind of treatment climacteric syndrome provided by the invention, medicine especially senile, the atrophic female vagina contains the sodium prasterone sulfate of medicinal effective dose, and described sodium prasterone sulfate is that particle size range is 0.1 micron～500 microns a micro powder granule.
A kind of treatment climacteric syndrome provided by the invention, medicine especially senile, the atrophic female vagina contains sodium prasterone sulfate and the pharmaceutically useful carrier and/or the excipient of medicinal effective dose.
The adoptable dosage form of medicine of the present invention is tablet, capsule, granule, suppository, ointment, injectable powder or other dosage forms.
When the dosage form of medicine employing of the present invention is injection, can contain sodium prasterone sulfate and conventional solvent, for example water for injection.When the dosage form of medicine employing of the present invention is ointment, can contain sodium prasterone sulfate and conventional ointment base.
When medicine provided by the invention is tablet, granule or capsule, can contain sodium prasterone sulfate 0.5～98% (percetage by weight), preferred 1～50%, and pharmaceutically useful adjuvant.The content of described sodium prasterone sulfate, according to conventional pharmaceutical technology, according to the dosage form difference, the consumption difference is very big, as capsule, can reach more than 90%, and tablet will much less.The type of adjuvant and content are decided according to conventional pharmaceutical technology, and for example, diluent or filler can be 0.1～95%, and binding agent can be 0.1～30%, and disintegrating agent can be 0.5～30%, and lubricant can be 0.5～3%.Also can add an amount of correctives as needs.Also can contain vitamin C, E, D, trace element, antioxidant etc. in the medicine provided by the invention.
The structural formula of described sodium prasterone sulfate is as follows:
Its chemical name is 3 beta-hydroxies androstane-5-alkene-17-ketone sulfuric ester sodium salt.
It is a kind of in lactose, mannitol, sorbitol, xylitol, starch and derivant thereof, dextrin, the silicon dioxide or several that described diluent can be selected diluent for use.Its content is according to conventional pharmaceutical technology, with dosage form and technology and decide, can be 1%～95%.
It is a kind of in dextrin, starch, pregelatinized Starch, polyvinyl alcohol, Sodium Tvlose, the Hydroxyalkyl propyl group methylcellulose or several that described binding agent can be selected binding agent for use.
Described disintegrating agent is a kind of in starch, pregelatinized Starch, microcrystalline Cellulose, Sodium Tvlose, the low-substituted hydroxypropyl cellulose or several.Its content range can be 1%～20%.
Medicine of the present invention can be made according to conventional method by active component sodium prasterone sulfate and various adjuvant.
The preparation method of medicine of the present invention can be that earlier according to conventional method the active component sodium prasterone sulfate to be processed into particle size range be 0.1 micron～500 microns micro powder granule, again itself and various adjuvant is prepared medicine of the present invention according to conventional method.
That the method for application of medicine of the present invention has is oral, mucosa or skin absorbs, intravenous injection etc.
Dosage every day during medicament administration of the present invention can be 10mg to 2000mg.
Medicine provided by the invention is to climacteric syndrome, especially senile, atrophic female vagina has better curative effect, and clinical drug effect of the present invention relaxes, toxic and side effects is little, non-stimulated to endometrium, can not cause vaginal hemorrhage, the carcinogenic risk that does not have common hormonotherapy to bring.
The pharmacodynamic experiment result of medicine provided by the invention also proves: medicine of the present invention has the excision of promotion ovary rat uterus weight increase effect; Make uterus body of gland number increase effect; The effect that promotes to extract ovary rat postpartum estrus is arranged, vagina superficial cell number is increased, and dose-effect relationship and time-effect relationship height correlation.Show that medicine of the present invention has estrogen-like effects.Zoopery is the result also show: pharmaceutical preparation of the present invention organized and used livial excision ovary to the proliferative effect of extracing ovary animal uterus inner membrance than the intact animal matched group is all little.These results show that medicine of the present invention is very little to the endometrium stimulation.Medicine of the present invention has obvious effect to the cleaning vagina.Clinical experiment also prove medicine of the present invention to the treatment climacteric syndrome, especially treat senile, the atrophic vaginitis of women, better curative effect is arranged.
Active component sodium prasterone sulfate in the medicine of the present invention optionally acts on target tissue.Therefore, very little to the endometrium stimulation, can not cause vaginal hemorrhage, the carcinogenic risk that does not have hormone to bring.And common hormonotherapy causes easily and side effect such as vaginal hemorrhage has carcinogenic danger.So medicine of the present invention has overcome the shortcoming of existing medicine, be the treatment climacteric syndrome, especially treat senile, the atrophic vaginitis of women, good effect, the little medicine of side effect.
Description of drawings
Fig. 1 is the microphotograph of normal group endometrium and body of gland section.
Fig. 2 is the microphotograph of excision group endometrium and body of gland section.
Fig. 3 is the microphotograph of pharmaceutical preparation small dose group endometrium of the present invention and body of gland section.
Fig. 4 is the microphotograph of dosage group endometrium and body of gland section in the pharmaceutical preparation of the present invention.
Fig. 5 is the microphotograph of pharmaceutical preparation of the present invention heavy dose of group endometrium and body of gland section.
Fig. 6 is the microphotograph of Comparative formulation group endometrium and body of gland section.
After Fig. 7 is the oral pharmaceutical preparation provided by the invention of patient, the body inner blood Chinese medicine concentration and the time relation figure that takes medicine.
The specific embodiment
Embodiment 1
Sodium prasterone sulfate (the general testosterone sodium of medicinal sulphuric acid meets Chinese Pharmacopoeia version in 2000, Yangzhou, Jiangsu pharmaceutical factory produce) 25 grams are processed into powdery by methods such as jet mills, and to make particle diameter be 20～100 microns.With powdery sodium prasterone sulfate and 39 gram pregelatinized Starch (pregelatinized Starch, medicinal, Chinese Pharmacopoeia version in 2000, Huzhou food chemical industry affiliated company produces) and 16 gram microcrystalline Cellulose (microcrystalline Cellulose, medicinal, Chinese Pharmacopoeia version in 2000, Shanghai Zhao Tun pharmaceutical factory produces) mix homogeneously, the starch slurry that adds concentration and be 10% (percetage by weight) an amount of (its addition so that gained mixture be fit to according to a conventional method granulate be advisable), mix homogeneously is made soft material, and 20 order nylon mesh are granulated, 50 ℃ of dryings 2 hours, 18 mesh sieve granulate add 5 ‰ (accounting for finished weight) magnesium stearate, mixing, tabletting makes diameter and is 1000 pharmaceutical preparation A provided by the invention of 6 millimeters.
Embodiment 2
According to the method for embodiment 1 sodium prasterone sulfate (the general testosterone sodium of medicinal sulphuric acid meets Chinese Pharmacopoeia version in 2000, and Yangzhou, Jiangsu pharmaceutical factory produces) of commercially available common granularity is mixed with pharmaceutical preparation B of the present invention with other components.
Embodiment 3
Disintegrate, dissolving out capability behind mobility of particle, tabletting complexity and the tabletting of investigation embodiment 1 gained preparation A the results are shown in the following table.From the table data as seen, preparation A mobility of particle is good, the tablet molding is good, disintegration, dissolution etc. all meets the requirements.
Quality examination result behind table 1 tabletting
Embodiment 4
One, supply the preparation of test agent:
1, according to the requirement of experiment grouping, the preparation A that gets embodiment 1 gained is a certain amount of, is milled to powder with mortar, adds injection water 100ml, according to the test liquid of different amounts preparation variable concentrations.
2, Comparative formulation: by active component livial (the different alkynes promise of 7-methyl copper 2.5mg/ sheet, the import of Holland Ou Jianong company, the commercial goods of Nanjing Ou Jianong pharmaceutical Co. Ltd packing under the supervision of Dutch Ou Jianong company and exclusive the mandate, lot number: L9-4750-10, authentication code: (96) are defended the accurate word J-08 of medicine number).Add injection water 100ml, make certain density livial suspension.The rat dosage is 0.284mg/kg.
3, normal group, model control group gives water for injection.
Two, laboratory animal:
The SD rat, female, body weight: 200-220g (is provided by the department of the Chinese Academy of Sciences of Department Of Medicine, Peking University's laboratory animal section.The quality certification number: the moving word 01-3049 of doctor).Animal feeding condition: room temperature: 25 ℃, humidity: air draft in 65%, 24 hour, freely drink water.Feedstuff: Beijing Experimental Amimal Research Centre provides, No. 1, common Mus full-valence pellet feed, No. the 009th, the accurate word (1994) of the moving pipe in capital, No. the 007th, capital moving pipe matter word (1994).
Three, experiment grouping:
Irritating the stomach mode, give following group of rat for test agent by the capacity of every 100g body weight 0.5ml.
Normal control group: claim normal group, give not extract the volume injection waters such as rat of ovary.
Model control group: claim the excision group, give to extract the volume injection waters such as rat of ovary.
Heavy dose of group: give to extract the test liquid that contains pharmaceutical preparation A provided by the invention that an amount of embodiment 1 of rat of ovary makes, so that dosage is the sodium prasterone sulfate of 250mg/kg.
In the dosage group: give to extract the test liquid that contains pharmaceutical preparation A provided by the invention that an amount of embodiment 1 of rat of ovary makes, so that dosage is the sodium prasterone sulfate of 50mg/kg.
Small dose group: give to extract the test liquid that contains pharmaceutical preparation A provided by the invention that an amount of embodiment 1 of rat of ovary makes, so that dosage is the sodium prasterone sulfate of 10mg/kg.
Positive controls claims the Comparative formulation group, gives to extract the rat 0.284mg/kg livial of ovary.
Four, experimental technique:
1, senile, atrophic vaginitis modelling:
Extract operation on ovary: will test Mus and anaesthetize with pentobarbital sodium, the abdomen position is fixed, get under the most last rib, internal organs center line and apart from the about 2cm infall in the spinal column outside, wipe out and become mildewed, cut skin and the about 1.5-2cm of dorsal muscles, the shinny liparitosis of a visible milky in the otch visual field just can be seen the ovary of pink or yellowish red color, during clip, earlier with fallopian tube under the ovary together with the fat ligation, extract ovary again, postoperative is taken advantage of a situation cornua uteri is sent back in the abdominal cavity, extracts opposite side ovary (Zhu Yu with method, many elegant seas are edited " disease model of laboratory animal " Tianjin Scientific English Translation publishing company and are published 1997).
Smear: draw a small amount of normal saline with dropper, insert postoperative and raise about 0.5cm in 5 days the rat vagina through cleaning, suction for several times repeatedly.Then fluid drips is inhaled in microscope slide by institute, after drying naturally, bubble was gone in 5% the U.S. blue dyeing liquor 10 minutes, and water washes down, and does and then observes in microscopically.
Observe rutting period: dioestrus, mainly contain a large amount of multinuclear leukocyte, and a spot of epithelial cell is also arranged.Proestrus has a large amount of epithelial cells, and endochylema still has a small amount of superficial cell in pelletized form, but does not have leukocyte.Mainly contain a large amount of superficial cells rutting period, shape is big and irregular, and a small amount of epithelial cell is arranged.Metoestrus has a large amount of leukocyte, and the superficial cell of fusion is arranged.
Vagina cleanness degree: judge cleannes with the numeration of leukocyte in the vaginal smear with reference to clinical human vagina's cleannes decision method (Jiang Sen, Teng Qingzhu chief editor " gynecology " Shandong science tech publishing house, 1,986 9 pages of March on days).
Flaking method: will be through the blue painted vaginal smear of U.S. with 10% formalin fixed 10 minutes, flushing is after H.E (hematoxylin, Yihong) dyes reuse ethanol at different levels (70%-80%-90%-95%-95%-100%-100%-dimethylbenzene-dimethylbenzene) color separation dehydration transparent-sealing (natural gum).
Observational technique: add up leukocyte count under high power microscope, each opens smear counting 5 the different visuals field, computation of mean values again:
Cleannes I-5 visual field leukocyte count average is less than 50.
Cleannes II-5 visual field numeration of leukocyte average is at 50～200.
Cleannes III-5 visual field numeration of leukocyte＞200～1500.
Decision method:
(1) judges (calculating) with what number of animals of leukocyte count in the smear through definite probabilistic method.
(2) with numeration of leukocyte (carrying out the t check).
2, test:
Selected continuous smear for use five days, and estrous rat all do not occur and carry out following test.
Administration is carried out in three batches, respectively according to following method administration 20 days, 30 days, 50 days.And the next day after the last administration carry out plate coating checking, the sacrificed by decapitation rat then of weighing in the abdomen median line, is cut off the abdominal cavity, extracts the uterus, weighs, and steeps then and carry out pathological section in 10% formalin solution, does inspection mirror under.
Observation index: vagina superficial cell (vaginal smear), vagina cleanness degree, uterus weight (weight method), endometrium and body of gland (pathological section).
Five, result of the test:
(1) to the influence of vagina superficial cell
Except that normal group, respectively organize the vaginal smear superficial cell before the administration and be zero, below account for the percent of this treated animal sum for the number of animals in each group smear cycle of living in.
The influence of table 2. pair rat vagina superficial cell
| 20 days (%) | 30 days (%) | 50 days (%) | ||||||||||||||||
| Group | n | 0 | + | ++ | +++ | -- | n | 0 | + | ++ | +++ | ++++ | n | 0 | + | ++ | +++ | ++++ |
| Normal group | 10 | -- | -- | 30 | 40 | 30 | 10 | -- | -- | 10 | 20 | 30 | 10 | -- | -- | -- | 20 | 80 |
| The excision group | 10 | 40 | 40 | 20 | -- | -- | 10 | 40 | 60 | -- | -- | -- | 10 | 40 | 50 | 10 | -- | -- |
| Positive group | 11 | -- | 9 | 18 | 18 | 55 | 10 | -- | 10 | 10 | -- | 80 | 8 | -- | -- | 13 | 37 | 50 |
| Small dose group | 11 | -- | 55 | 27 | 9 | -- | 10 | 30 | 20 | 50 | -- | -- | 9 | -- | 22 | 45 | 33 | -- |
| Middle dosage group | 10 | -- | 30 | 30 | 20 | 20 | 9 | -- | -- | 44 | 33 | 22 | 8 | -- | -- | 25 | 50 | 25 |
| Big metering group | 10 | -- | 10 | 40 | 10 | 40 | 10 | -- | -- | -- | 50 | 50 | 9 | -- | -- | 11 | 33 | 56 |
Remarks: 0 does not see keratinocyte ,+accidental keratinocyte, ++ diversification cell slightly, +++more keratinocyte, ++ ++ a large amount of keratinocytes; N is a number of animals, and other data are %,--be 0.
The rat vagina smear results sees Table 2, therefrom can find out:
1. normal group animal major part is in diversification cell (10～30%), more keratinocyte (20%～40%) and a large amount of keratinocyte (30～80%) state slightly.
2. extracing the most of smear of treated animal does not have keratinization cell (40%) and accidental keratinocyte (40,50,60%) state, and small part is diversification cell (10～a 20%) state slightly.
3. positive drug control group: the fraction animal is accidental keratinocyte (a 10%) state, and part is diversification cell (10～20%) and more keratinocyte (20～30%) state slightly, mainly is a large amount of keratinocytes (60,80,40%) states.So along with the prolongation keratinocyte of administration time has the trend of increasing.
4. use the small dose group (10mg/kg) of pharmaceutical preparation A of the present invention:
Mainly be accidental keratinocyte (60%) state in the time of 20 days, part is diversification cell (30%) and more keratinocyte (10%) state slightly.Partly being no keratinization cell (30%) and accidental keratinocyte (20%) state in the time of 30 days, mainly is diversification cell (50%) state slightly.Partly being accidental keratinocyte (20%) in the time of 50 days, mainly is diversification cell (45%) and more keratinocyte (33%) state slightly.So superficial cell has the trend of increasing with the prolongation of administration time.
5. use the middle dosage group (50mg/kg) of pharmaceutical preparation A of the present invention:
Animal is distributed in accidental keratinocyte (30%), diversification cell (30%), more keratinocyte (20%) and a large amount of keratinocyte (20%) state slightly in the time of 20 days.Mainly diversification cell (45%), more keratinocyte (33%) and a large amount of keratinocyte (22%) state slightly in the time of 30 days.Partly be diversification cell (25%) slightly in the time of 50 days, mainly be distributed in more keratinocyte (50%) and a large amount of keratinocyte (25%) state.
6. use the heavy dose group (250mg/kg) of pharmaceutical preparation A of the present invention:
Partly be accidental keratinocyte (10%) state in the time of 20 days, mainly be diversification cell (40%), more keratinocyte (10%) and a large amount of keratinocyte (40%) state slightly.Mainly be distributed in more keratinocyte (50%) and a large amount of keratinocyte (50%) state in the time of 30 days.Part diversification cell (11%) and more keratinocyte (33%) state slightly mainly is a large amount of keratinocytes (56%) states in the time of 50 days.
Can find out that from The above results medicine of the present invention has the effect of the excision of promotion ovary rat postpartum estrus, the vagina superficial cell number that makes that dose-effect relationship presents dose dependent increases.Administration 20,30,50 days is to increase vagina superficial cell number the most for a long time, three dosage groups are respectively 0.9333 (20 days), 0.9559 (30 days) 0.9537 (50 days) by the correlation coefficient r that the conventional statistical method of pharmacology calculates, and show height correlation (being that amount of drug and the increase of vagina superficial cell number have very big relation).The correlation coefficient that time-effect relationship calculated 20,30,50 days by the conventional statistical method of pharmacology is respectively r=0.9972 (50mg/kg), r=0.9449 (250mg/kg), shows height correlation (service time and the increase of vagina superficial cell number that are medicine have very big relation).Illustrate that medicine of the present invention has played estrogen-like effects, obviously promote vagina to recover normal, effectively alleviate senile, the atrophic vaginitis patient vagina discomfort that for want of estrogen caused, drying, easy symptom such as inflammation.
(2) vagina cleanness degree
Table 3 has been listed the result of the cleannes of rat.
The number of animals of the oral pharmaceutical preparation of the present invention of table 3. rat and 30 days different cleaning degree of Comparative formulation
| Group | Number of animals | Cleannes | ||
| I | II | III | ||
| The excision group | 9 | 1 | 1 | 7 |
| The Comparative formulation group | 9 | 6 △△ | 2 | 1 △△ |
| Small dose group (10mg/kg) | 9 | 6 △ | 0 | 3 △ |
| Middle dosage group (50mg/kg) | 9 | 6 △ | 1 | 2 △ |
| Heavy dose of group (250mg/kg) | 10 | 7 △△ | 2 | 1 △△ |
The definite probabilistic method of learning is by statistics calculated: △ represents diversity factor P＜0.05, and △ △ represents diversity factor P＜0.01
The result shows: the self-cleaning action of 1. excision group rat vagina is the poorest, so III degree number of animals is 7, and the visible down leukocyte of expiring the visual field of mirror.The visible I of individual animal smear, II degree may be relevant with experimental implementation.2. give three dosage groups of pharmaceutical preparation A of the present invention, increase with dosage, III degree number of animals obviously reduces, small dose group (10mg/kg) III degree accounts for 33% (P＜0.05 is represented variantly, and promptly medicine and rat cleannes have relation), middle dosage group III degree accounts for 22% (P＜0.05), heavy dose of group III degree accounts for 10% (P＜0.01, expression has notable difference, promptly medicine and rat cleannes have significant correlation).I, II degree small dose group, middle dosage group and heavy dose of group are respectively 67%, 78% and 90%.3. the heavy dose group vagina self-cleaning action of pharmaceutical preparation A of the present invention and Comparative formulation group (I, II degree account for 89%, III degree account for 11%) are similar.So medicine of the present invention can improve the cleannes of vagina, can treat senile, atrophic vaginitis.
The numeration of leukocyte of rat vagina smear H.E dyeing back under high power lens of excision group, Comparative formulation group and preparation various dose group of the present invention the results are shown in Table 4.
The oral preparation of the present invention of table 4 rat is to the influence of vagina cleanness degree
| Group | Number of animals | Cleannes | ||
| I | II | III | ||
| The excision group | 9 | 28.0(1) | 130.0(1) | 1292.86±274.51(7) |
| The Comparative formulation group | 9 | 9.20±19.08(6) | 136.0±16.97(2) | 340.0(1) |
| Small dose group (10mg/kg) | 9 | 2.93±4.85(6) | 509.67±365.50(3)** | |
| Middle dosage group (50mg/kg) | 9 | 8.13±10.84(6) | 63.0 | 672.0±393.15(2)* |
| Heavy dose of group (250mg/kg) | 10 | 3.25±6.10(7) | 113.8±7.92(2) | 890.0(1) |
Compare * with the excision group and represent P＜0.05, * * represents that the number in P＜0.01 bracket is the animal number.
The result as seen from table: 1. excision group vagina cleanness degree serves as many (n=7) with the III degree, and leukocyte is the full visual field, about 1000-1500 of counting average under the high power field.Though the administration group has the III degree, cell number obviously reduces, and the low dose of preparation of the present invention is compared with the excision group with middle dosage group all significant difference (P＜0.05 and P＜0.01, the same, promptly medicine and rat cleannes are respectively that relation and significant correlation are arranged).2. each dosage group vagina cleanness degree of preparation of the present invention is many with the I degree all, and cell number obviously reduces (2～8), is 1 so can't add up because of excision group I degree number of animals.
Pharmaceutical preparation of the present invention can improve the cleannes of vagina, and the intravaginal leukocyte count is obviously reduced.The effect of heavy dose of group is similar to the Comparative formulation group.Medicine of the present invention is senile to treating, atrophic vaginitis, cleaning vagina, and obvious curative effects is arranged.
(3). to the influence of uterus weight
Investigation to the uterus weight of each treated animal the results are shown in Table 5 and 6.The excision group: each time point of uterus weight does not have change substantially, all maintains the 0.16g level, so the administration group is compared with the excision group.
Table 5 preparation of the present invention is to extracing ovary rat uterus weight (g, the influence of X ± SD)
| Group | 20 days | 30 days | 50 days |
| Normal group | 0.5368±0.1021 | 0.7069±0.2803 | 0.6343±0.2616 |
| The excision group | 0.1641±0.0326 | 0.1692±0.0397 | 0.1856±0.0367 |
| The Comparative formulation group | 0.2621±0.0745** | 0.3375±0.0557** | 0.3446±0.0715** |
| Small dose group (10mg/kg) | 0.1566±0.0087△△ | 0.2036±0.0426△△ | 0.1539±0.0131△△ |
| Middle dosage group (50mg/kg) | 0.2157±0.0419** | 0.2245±0.0319**△△ | 0.2299±0.0643△△ |
| Heavy dose of group (250mg/kg) | 0.2555±0.0332** | 0.3301±0.0966** | 0.2879±0.0728** |
Each treated animal number is with table 4, with excision group ratio
*Expression p＜0.01 is compared △ △ with the Comparative formulation group and is represented p＜0.01
Table 6 preparation of the present invention is to extracing ovary rat uterus coefficient (* 10
-5) influence
| Group | n | 20 days | n | 30 days | n | 50 days |
| Normal group | 10 | 217±42 | 10 | 273±103 | 10 | 220±93 |
| The excision group | 10 | 53±11 | 10 | 53±14 | 10 | 52±9 |
| The Comparative formulation group | 10 | 88±23** | 10 | 123±19** | 8 | 119±28** |
| Small dose group (10mg/kg) | 10 | 52±6△△ | 10 | 63±18△△ | 9 | 44±6*△△ |
| Middle dosage group (50mg/kg) | 9 | 72±13** | 9 | 61±13△△ | 8 | 63±18△△ |
| Heavy dose of group (250mg/kg) | 8 | 84±12** | 9 | 81±49△ | 9 | 89±22**△ |
The n=number of animals; Uterus coefficient=uterus weight/body weight; Compare with the excision group:
*Expression p＜0.05,
*Expression p＜0.01; Compare with the Comparative formulation group: △ represents p＜0.05, and △ △ represents p＜0.01.
The middle dosage group of pharmaceutical preparation of the present invention, rat uterus weight be in administration 20 days (0.2157g), 30 days (0.2245g), and comparing with excision group (0.1692g) all has increase.The heavy dose group uterus weight of pharmaceutical preparation of the present invention is in administration 20 days (0.2555g), 30 days (0.3301g), and comparing with excision group (0.1692g) all has increase.Learn method result of calculation by statistics and show significant difference is arranged (P＜0.01, be medicine and rat uterus weight significant correlation), the heavy dose group (0.2879 of administration 50 days pharmaceutical preparation C group of the present invention (0.2299g) and pharmaceutical preparation of the present invention, P＜0.01, being medicine and rat uterus weight significant correlation) uterus weight has increase slightly, see Table 5, the uterus coefficient that the heavy dose group of pharmaceutical preparation of the present invention is removed by body weight with uterus weight represents to still have significant difference (P＜0.01), sees Table 6.
The heavy dose group uterus weight of administration pharmaceutical preparation of the present invention in the time of 20,30 days (0.2555g, 0.3301g), with positive control drug Comparative formulation group (0.2621g, 0.3375g) similar substantially.The middle dosage group administration of pharmaceutical preparation of the present invention 20 days, 30 days, uterus weight also have increase (P＜0.01).
Medicine of the present invention has the effect that promotes that uterus weight increases, and medicine promptly of the present invention has significant estrogen-like effects to rat uterus.
(4) to the morphologic influence in uterus
Sample disposal: get the uterus, the cross-section uterine cavity in about 1cm place is drawn materials below crotch respectively, routine paraffin wax embedded section, HE dyeing.
Observational technique: measure the endometrium thickness of every rat respectively, counting body of gland quantity, matter situation between observation body of gland form reaches, every treated animal calculates average inner film thickness and body of gland quantity.
Inner film thickness and body of gland quantity result of calculation see Table 7, therefrom can find out, the small dose group endometrium of pharmaceutical preparation of the present invention is compared no significant difference (p＞0.05 with the excision group, be that medicine and rat endometrium thickness are irrelevant), group was compared with the excision group in 20 days, 30 days, made uterus body of gland number increase effect.Medicine of the present invention does not have influence to endometrial hypertrophy, illustrates endometrium is had no stimulation.Medicine of the present invention obviously promotes the uterine glands bulk-growth, thereby effectively alleviates the drying of vagina, the treatment vaginitis.
Average inner film thickness of each treated animal of table 7 and body of gland quantity (X ± SD)
| Group | 20 days | 30 days | 50 days | |||
| Inner film thickness | Body of gland quantity | Inner film thickness | Body of gland quantity | Inner film thickness | Body of gland quantity | |
| Normal group | 0.12±0.02 | 6.10±0.99 | 0.12±0.04 | 4.44±1.74 | 0.16±0.06 | 7.00±2.44 |
| The excision group | 0.08±0.01 | 3.44±1.01 | 0.07±0.02 | 2.22±0.97 | 0.08±0.02 | 4.77±0.92 |
| The Comparative formulation group | 0.10±0.02* | 3.62±2.19 | 0.11±0.01** | 4.57±1.13 | 0.12±0.04* | 5.42±1.39 |
| Small dose group (10mg/kg) | 0.08±0.02 | 4.12±1.24 | 0.07±0.01△△ | 3.55±1.06** | 0.07±0.02△△ | 4.70±1.33 |
| Middle dosage group (50mg/kg) | 0.11±0.02** | 5.33±0 86**△ | 0.09±0.01*△△ | 5.00±2.20** | 0.10±0.02 | 4.12±1.64 |
Inner film thickness unit: mm, body of gland unit of quantity: body of gland number/each tangent plane; Each treated animal number is with table 2,
Compare with the excision group:
*Expression p＜0.05,
*Expression p＜0.01; Compare with the livial group: △ represents p＜0.05, and △ △ represents p＜0.01.
The observed result of matter situation was seen microphotograph Fig. 1 of each experimental group rat endometrium and body of gland section, 2,3,4,5 and 6 between the body of gland form in uterus reached after 30 days.After 30 days, intermembranous matter is more loose in the normal group, and the body of gland flexibility increases, and the glandular epithelium cube has the phenomenon of vacuolation, and a matter is based on spindle cell, and is abundanter, sees Fig. 1 (amplification: 40).The excision group changes more remarkable, the volume atrophy, and the inner membrance attenuation, a matter has fibrosis, sees Fig. 2 (amplification: 40).Use and the invention provides the preparation group all based on simple tubular gland, the body of gland flexibility increases not obvious, brached tubular gland appears in middle dosage (50mg/kg) and heavy dose of group (250mg/kg) individual animal, 100), 4 (amplifications: 100) and 5 (amplifications: 100) the body of gland epithelium is cube or high column physaliphore, sees Fig. 3 (amplification:.Comparative formulation group inner membrance is thicker, and body of gland is more sparse, and part is cystic atrophy, sees Fig. 6 (amplification: 100).Can find out that from these results pharmaceutical preparation provided by the invention is non-stimulated to endometrium, can increase uterus body of gland number, help alleviating climacteric syndrome.
Embodiment 5
Drug level after the measurement patient takes medicine in the serum:
Give 45～55 years old oral preparation A medicine provided by the invention of climacteric women (dosage: disposable oral 100mg), test the concentration of different times blood in human body in liquid Chinese medicine.
With U.S. Diagnostic Systems Laboratories, the special-purpose DSL-10-3500 kit of the EIA serum that Inc produces is measured sodium prasterone sulfate concentration in the blood sample.
Experimental result is seen Fig. 7, and vertical coordinate is a sodium prasterone sulfate concentration among the figure, and abscissa is the time to measuring drug level of taking medicine.As seen from the figure, the very fast rising of sodium prasterone sulfate concentration in the serum reached peak value in about 1 hour behind the oral preparation A provided by the invention, and the half-life is about 12～18 hours.Illustrate that medicine of the present invention is absorbed by the body easily.
Embodiment 6,
Observation contains the pharmaceutical preparation provided by the invention of varigrained sodium prasterone sulfate to 12 clinical effectiveness (Beijing large hospital) of suffering from the menopausal syndrome patient
The patient is divided into two groups, takes medicine B provided by the invention for first group, and another group is taken pharmaceutical preparation A of the present invention; Oral for each person every day 100mg took 3 months.Improvement situation with conventional Kupperman standards of grading and vaginal smear observation menopausal syndrome and senile atrophic vaginitis.
The result show take medicine of the present invention after, menopausal syndrome and senile atrophic vaginitis all have improvement, and the doing well,improving of wherein taking the 6 routine climacteric syndrome symptoms of pharmaceutical preparation A provided by the invention and atrophic vaginitis patient significantly is better than 6 examples of pharmaceutical preparation B provided by the invention.
Claims (1)
1, the application in the medicine of sodium prasterone sulfate, atrophic female vagina senile in preparation treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02158544 CN1231217C (en) | 2002-12-25 | 2002-12-25 | Medicine for treating climacteric syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02158544 CN1231217C (en) | 2002-12-25 | 2002-12-25 | Medicine for treating climacteric syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1509719A CN1509719A (en) | 2004-07-07 |
| CN1231217C true CN1231217C (en) | 2005-12-14 |
Family
ID=34237041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02158544 Expired - Lifetime CN1231217C (en) | 2002-12-25 | 2002-12-25 | Medicine for treating climacteric syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1231217C (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102429912B (en) * | 2011-10-26 | 2013-04-24 | 庞飞 | Pharmaceutical composition prepared with micronized prasterone or sodium prasterone sulfate and use thereof |
| CN104983706B (en) * | 2015-06-04 | 2018-10-30 | 湖北生物医药产业技术研究院有限公司 | Sodium Prasterone Sulfate sustained release tablets and its preparation process |
| CN104983717A (en) * | 2015-06-04 | 2015-10-21 | 湖北生物医药产业技术研究院有限公司 | Sodium prasterone sulfate sustained-release capsule and preparation method thereof |
| CN104983705B (en) * | 2015-06-04 | 2018-11-30 | 湖北生物医药产业技术研究院有限公司 | Sodium Prasterone Sulfate sustained release tablets and preparation method thereof |
| CN104983696A (en) * | 2015-06-04 | 2015-10-21 | 湖北生物医药产业技术研究院有限公司 | Sodium prasterone sulfate dispersible tablet and preparation method thereof |
| SE1750680A1 (en) * | 2017-05-30 | 2018-12-01 | Peptonic Medical Ab | Composition for treating or preventing climacteric disorders |
-
2002
- 2002-12-25 CN CN 02158544 patent/CN1231217C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1509719A (en) | 2004-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1289137C (en) | Medicine for treating mammary gland proliferation, its preparation method and application | |
| CN1231217C (en) | Medicine for treating climacteric syndrome | |
| CN1742938A (en) | Lifukang medicine for vagina and preparing method thereof | |
| CN1709243A (en) | Vagina medicine containing ebselen and its use | |
| CN1785292A (en) | Medicine for treating flooding and spotting and its preparation method | |
| CN1167438A (en) | Novel hormonal medicaments and use thereof for correcting oestrogen deficiencies | |
| CN1891224A (en) | Progestational hormone composition, and its slow-release suppository device and preparation of said device | |
| CN1270776C (en) | Ulcer quieting medicine its preparation and use | |
| CN109248166A (en) | The preparation and application of Anastrozole depot pesseulum | |
| CN1903351A (en) | Funing gel prepn. and its prepn. method | |
| CN1911260A (en) | Application of phenolic acids active components from dandelion for inhibiting gynecologic pelvic inflammatory disease | |
| CN103463276B (en) | Mammary gland hyperplasia treatment drug composition and preparation method thereof | |
| CN1695635A (en) | Oral compound preparation for treating skin disease | |
| CN1857274A (en) | Medicine composition for treating valval and/or vaginal infection | |
| CN108339002B (en) | Compound medroxyprogesterone acetate composition for pets and application thereof | |
| CN1209126C (en) | New use of ledebouriella root | |
| CN101032589A (en) | Gynaecological inflammation-treating medicine and its preparation | |
| CN1197571C (en) | Metronidazole, Clotrimazole and Chlorhexidime Acetate preparation and its preparing method | |
| CN110432383A (en) | It is a kind of to promote the sexual maturity the mongolian veterinary drug additive and preparation method thereof of progestogenic for ewe | |
| CN1887288A (en) | Medicine for treating endometriosis and its prepn | |
| CN103908435A (en) | Flutamide sustained release preparation and its preparation method | |
| CN1241571C (en) | Use of centella total glycoside in manufacture of medicine | |
| CN115025108B (en) | A pharmaceutical composition for treating pelvic inflammatory disease and preparation method thereof | |
| EP2578206A1 (en) | Pharmaceutical composition for the treatment of disorders of the lower section of the urogenital system | |
| CN116808004A (en) | Tamoxifen mammary gland transdermal patch and preparation process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: MAYINGLONG PHARMACEUTICAL GROUP CO., LTD. Effective date: 20150617 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20150617 Address after: 100006, room 86, 510 South Main Street, Beijing, Dongcheng District Patentee after: Pang Fei Patentee after: MAYINGLONG PHARMACEUTICAL GROUP Co.,Ltd. Address before: 100006, room 86, 510 South Main Street, Beijing, Dongcheng District Patentee before: Pang Fei |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20051214 |